Skip to main content

Compare Stocks

Date Range: 

 Infinity PharmaceuticalsAlpine Immune SciencesiBioNextCureMustang Bio
SymbolNASDAQ:INFINASDAQ:ALPNNYSEAMERICAN:IBIONASDAQ:NXTCNASDAQ:MBIO
Price Information
Current Price$2.89$12.62$1.36$8.01$2.86
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.61.81.31.61.6
Analysis Score4.43.53.53.23.5
Community Score2.02.53.12.62.4
Dividend Score0.00.00.00.00.0
Ownership Score0.82.50.01.71.7
Earnings & Valuation Score0.60.60.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$9.00$19.40$2.50$22.55$10.00
% Upside from Price Target211.42% upside53.72% upside83.82% upside181.47% upside249.65% upside
Trade Information
Market Cap$256.19 million$301.58 million$293.77 million$221.16 million$243.60 million
Beta2.41.72-5.81-0.41.85
Average Volume3,129,610113,48113,770,291240,2052,553,492
Sales & Book Value
Annual Revenue$3.05 million$1.74 million$1.64 million$6.35 millionN/A
Price / Sales84.00173.32179.1334.83N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.14 per share$1.59 per share$0.48 per share$14.13 per share$1.25 per share
Price / Book20.647.942.830.57N/A
Profitability
Net Income$-47,060,000.00$-41,850,000.00$-16,440,000.00$-33,740,000.00$-46,390,000.00
EPS($0.83)($2.28)N/A($2.15)($1.29)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,592.65%-606.16%-1,005.62%N/AN/A
Return on Equity (ROE)-1,358.77%-80.38%-55.71%-10.00%-90.84%
Return on Assets (ROA)-81.85%-30.76%-26.91%-9.51%-68.47%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.13%0.40%0.01%N/A
Current Ratio4.42%3.98%16.84%51.73%9.91%
Quick Ratio4.42%3.98%16.67%51.73%9.91%
Ownership Information
Institutional Ownership Percentage46.66%52.86%8.78%66.30%25.75%
Insider Ownership Percentage13.77%76.10%1.00%9.05%3.39%
Miscellaneous
Employees2357439062
Shares Outstanding88.65 million23.90 million216.01 million27.61 million85.18 million
Next Earnings Date7/29/2021 (Estimated)8/10/2021 (Estimated)5/17/2021 (Confirmed)8/5/2021 (Estimated)8/9/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Mustang Bio, Inc. (NASDAQ:MBIO) Given Average Rating of "Buy" by BrokeragesMustang Bio, Inc. (NASDAQ:MBIO) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - May 17 at 6:32 PM
Mustang Bio (NASDAQ:MBIO) Coverage Initiated at BTIG ResearchMustang Bio (NASDAQ:MBIO) Coverage Initiated at BTIG Research
americanbankingnews.com - May 17 at 5:04 PM
-$0.21 Earnings Per Share Expected for Mustang Bio, Inc. (NASDAQ:MBIO) This Quarter-$0.21 Earnings Per Share Expected for Mustang Bio, Inc. (NASDAQ:MBIO) This Quarter
americanbankingnews.com - May 16 at 8:14 AM
Mustang Bio (NASDAQ:MBIO) Announces  Earnings Results, Hits ExpectationsMustang Bio (NASDAQ:MBIO) Announces Earnings Results, Hits Expectations
americanbankingnews.com - May 15 at 12:06 PM
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European ...Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European ...
apnews.com - May 12 at 2:54 PM
Mustang Bio to Study CAR T-Cell Therapy in CD20-Positive Lymphoma, Leukemia PatientsMustang Bio to Study CAR T-Cell Therapy in CD20-Positive Lymphoma, Leukemia Patients
precisiononcologynews.com - May 10 at 12:51 PM
Mustang Bio Inc. (NASDAQ:MBIO) surprises bull, looks strong going forwardMustang Bio Inc. (NASDAQ:MBIO) surprises bull, looks strong going forward
marketingsentinel.com - May 10 at 12:51 PM
Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T TherapyMustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
finance.yahoo.com - May 10 at 7:50 AM
Research Analysts Issue Forecasts for Mustang Bio, Inc.s FY2022 Earnings (NASDAQ:MBIO)Research Analysts Issue Forecasts for Mustang Bio, Inc.'s FY2022 Earnings (NASDAQ:MBIO)
americanbankingnews.com - May 6 at 11:48 AM
 Brokerages Expect Mustang Bio, Inc. (NASDAQ:MBIO) Will Announce Earnings of -$0.20 Per Share Brokerages Expect Mustang Bio, Inc. (NASDAQ:MBIO) Will Announce Earnings of -$0.20 Per Share
americanbankingnews.com - April 28 at 3:04 PM
Mustang Bio, Inc. (NASDAQ:MBIO): It Is A Stock Worth Considering TodayMustang Bio, Inc. (NASDAQ:MBIO): It Is A Stock Worth Considering Today
marketingsentinel.com - April 27 at 7:44 AM
Mustang Bio to Participate in Chardans 5th Annual Genetic Medicines Manufacturing SummitMustang Bio to Participate in Chardan's 5th Annual Genetic Medicines Manufacturing Summit
marketwatch.com - April 23 at 2:13 AM
Ford Mustang Shelby GT500 adds carbon fiber accessoriesFord Mustang Shelby GT500 adds carbon fiber accessories
news.yahoo.com - April 18 at 7:21 PM
Could The Mustang Bio, Inc. (NASDAQ:MBIO) Ownership Structure Tell Us Something Useful?Could The Mustang Bio, Inc. (NASDAQ:MBIO) Ownership Structure Tell Us Something Useful?
finance.yahoo.com - April 16 at 2:01 PM
Mustang Bio Inc (MBIO)Mustang Bio Inc (MBIO)
investing.com - April 14 at 10:46 AM
When is Mustang Bio, Inc. (MBIO) going to be good investment?When is Mustang Bio, Inc. (MBIO) going to be good investment?
marketingsentinel.com - April 13 at 9:44 AM
Mustang Bio Inc. [MBIO] moved up 12.70: Why It’s ImportantMustang Bio Inc. [MBIO] moved up 12.70: Why It’s Important
dbtnews.com - March 26 at 2:30 PM
Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate HighlightsMustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 24 at 5:22 PM
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day(R)Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day(R)
marketwatch.com - February 27 at 3:45 AM
Mustang Bio, Inc.s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share PriceMustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price
finance.yahoo.com - February 15 at 8:55 AM
Mustang Bio, Inc. (NASDAQ:MBIO) Contineus To Thrive In 2021, As Its Stock Is Up 18.1% Year-To-DateMustang Bio, Inc. (NASDAQ:MBIO) Contineus To Thrive In 2021, As Its Stock Is Up 18.1% Year-To-Date
marketingsentinel.com - February 6 at 7:22 PM
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked ...Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked ...
apnews.com - February 3 at 5:36 AM
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency ("XSCID")Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency ("XSCID")
marketwatch.com - February 2 at 12:32 PM
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 ...Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 ...
omaha.com - December 21 at 12:23 PM
Non-Executive Director Lindsay Rosenwald Just Bought 100% More Shares In Mustang Bio, Inc. (NASDAQ:MBIO)Non-Executive Director Lindsay Rosenwald Just Bought 100% More Shares In Mustang Bio, Inc. (NASDAQ:MBIO)
finance.yahoo.com - December 18 at 8:40 AM
DateCompanyBrokerageAction
3/24/2021Infinity PharmaceuticalsTruist SecuritiesInitiated Coverage
3/23/2021Infinity PharmaceuticalsB. RileyLower Price Target
3/23/2021Infinity PharmaceuticalsWells Fargo & CompanyBoost Price Target
3/18/2021Infinity PharmaceuticalsTruist FinancialInitiated Coverage
2/25/2021Infinity PharmaceuticalsPiper SandlerInitiated Coverage
2/11/2021Infinity PharmaceuticalsOppenheimerBoost Price Target
2/5/2021Infinity PharmaceuticalsJPMorgan Chase & Co.Upgrade
6/27/2019Infinity PharmaceuticalsCIBCInitiated Coverage
1/7/2019Infinity PharmaceuticalsUBS GroupReiterated Rating
12/21/2020Alpine Immune SciencesHC WainwrightInitiated Coverage
8/26/2020Alpine Immune SciencesCowenInitiated Coverage
6/19/2020Alpine Immune SciencesWedbushBoost Price Target
5/26/2020Alpine Immune SciencesLADENBURG THALM/SH SHReiterated Rating
11/13/2019Alpine Immune SciencesPiper Jaffray CompaniesLower Price Target
8/13/2018Alpine Immune SciencesRaymond JamesInitiated Coverage
6/28/2018Alpine Immune SciencesCitigroupInitiated Coverage
1/21/2021iBioCantor FitzgeraldInitiated Coverage
11/18/2020iBioAlliance Global PartnersLower Price Target
1/15/2021NextCureBank of AmericaDowngrade
8/7/2020NextCureNeedham & Company LLCReiterated Rating
7/16/2020NextCureBenchmarkUpgrade
7/14/2020NextCureBTIG ResearchLower Price Target
7/13/2020NextCureMorgan StanleyDowngrade
7/13/2020NextCureJMP SecuritiesDowngrade
7/13/2020NextCureRoth CapitalDowngrade
7/13/2020NextCureSunTrust BanksDowngrade
(Data available from 5/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.